US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
USRE28819E
(en)
|
1972-12-08 |
1976-05-18 |
Syntex (U.S.A.) Inc. |
Dialkylated glycol compositions and medicament preparations containing same
|
US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4358603A
(en)
|
1981-04-16 |
1982-11-09 |
Syntex (U.S.A.) Inc. |
Acetal stabilized prostaglandin compositions
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
US4663281A
(en)
|
1984-03-22 |
1987-05-05 |
Mass Institute Of Technology |
Enhanced production of proteinaceous materials in eucaryotic cells
|
US4789633A
(en)
|
1984-04-19 |
1988-12-06 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
DE68921982T4
(de)
|
1988-06-14 |
1996-04-25 |
Cetus Oncology Corp |
Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
ATE151110T1
(de)
|
1988-09-02 |
1997-04-15 |
Protein Eng Corp |
Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5750373A
(en)
|
1990-12-03 |
1998-05-12 |
Genentech, Inc. |
Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
US5734033A
(en)
|
1988-12-22 |
1998-03-31 |
The Trustees Of The University Of Pennsylvania |
Antisense oligonucleotides inhibiting human bcl-2 gene expression
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
IE63847B1
(en)
|
1989-05-05 |
1995-06-14 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
JP3051162B2
(ja)
|
1989-09-20 |
2000-06-12 |
アボット ラボラトリーズ |
融合蛋白質の製造方法
|
WO1991005548A1
(en)
|
1989-10-10 |
1991-05-02 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
AU642932B2
(en)
|
1989-11-06 |
1993-11-04 |
Alkermes Controlled Therapeutics, Inc. |
Protein microspheres and methods of using them
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
DK0463151T3
(da)
|
1990-01-12 |
1996-07-01 |
Cell Genesys Inc |
Frembringelse af xenogene antistoffer
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
EP0517754A1
(en)
|
1990-03-02 |
1992-12-16 |
Repligen Corporation |
Antibody constructs with enhanced binding affinity
|
WO1991014438A1
(en)
|
1990-03-20 |
1991-10-03 |
The Trustees Of Columbia University In The City Of New York |
Chimeric antibodies with receptor binding ligands in place of their constant region
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
WO1992002551A1
(en)
|
1990-08-02 |
1992-02-20 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
EP0556328A4
(en)
|
1990-11-09 |
1994-06-08 |
Abbott Lab |
Bridging antibody fusion constructs
|
DK0574395T3
(da)
|
1990-11-09 |
2002-10-07 |
Stephen D Gillies |
Cytokin-immunkonjugater
|
CA2074825C
(en)
|
1990-12-14 |
2005-04-12 |
Daniel J. Capon |
Chimeric chains for receptor-associated signal transduction pathways
|
DK1471142T3
(da)
|
1991-04-10 |
2009-03-09 |
Scripps Research Inst |
Heterodimere receptor-biblioteker under anvendelse af fagemider
|
AU666852B2
(en)
|
1991-05-01 |
1996-02-29 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
A method for treating infectious respiratory diseases
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
GB9112536D0
(en)
|
1991-06-11 |
1991-07-31 |
Celltech Ltd |
Chemical compounds
|
CA2110799A1
(en)
|
1991-06-14 |
1992-12-23 |
Arnold H. Horwitz |
Microbially-produced antibody fragments and their conjugates
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
ES2227512T3
(es)
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
ATE249840T1
(de)
|
1991-12-13 |
2003-10-15 |
Xoma Corp |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US6271242B1
(en)
|
1992-02-10 |
2001-08-07 |
Bristol-Myers Squibb Co. |
Method for treating cancer using a tyrosine protein kinase inhibitor
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6010715A
(en)
|
1992-04-01 |
2000-01-04 |
Bertek, Inc. |
Transdermal patch incorporating a polymer film incorporated with an active agent
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6024975A
(en)
|
1992-04-08 |
2000-02-15 |
Americare International Diagnostics, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
ES2162823T5
(es)
|
1992-08-21 |
2010-08-09 |
Vrije Universiteit Brussel |
Inmunoglobulinas desprovistas de cadenas ligeras.
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
ES2230542T3
(es)
|
1993-03-25 |
2005-05-01 |
MERCK & CO., INC. |
Inhibidor del factor de crecimiento celular endotelial vascular.
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
ATE361759T1
(de)
|
1993-07-15 |
2007-06-15 |
Cancer Res Campaign Tech |
Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
EP0733070A1
(en)
|
1993-12-08 |
1996-09-25 |
Genzyme Corporation |
Process for generating specific antibodies
|
US5925376C1
(en)
|
1994-01-10 |
2001-03-20 |
Madalene C Y Heng |
Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
|
US5618709A
(en)
|
1994-01-14 |
1997-04-08 |
University Of Pennsylvania |
Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
|
WO1995020401A1
(en)
|
1994-01-31 |
1995-08-03 |
Trustees Of Boston University |
Polyclonal antibody libraries
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
AU3382595A
(en)
|
1994-07-29 |
1996-03-04 |
Smithkline Beecham Corporation |
Novel compounds
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
US5911995A
(en)
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
AU4755696A
(en)
|
1995-01-05 |
1996-07-24 |
Board Of Regents Acting For And On Behalf Of The University Of Michigan, The |
Surface-modified nanoparticles and method of making and using same
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
ES2194973T3
(es)
|
1995-01-17 |
2003-12-01 |
Brigham & Womens Hospital |
Transporte de inmunogenes transepitelial especifico del receptor.
|
GB9501567D0
(en)
|
1995-01-26 |
1995-03-15 |
Pharmacia Spa |
Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
|
US5998596A
(en)
|
1995-04-04 |
1999-12-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibition of protein kinase activity by aptameric action of oligonucleotides
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5983134A
(en)
|
1995-04-23 |
1999-11-09 |
Electromagnetic Bracing Systems Inc. |
Electrophoretic cuff apparatus drug delivery system
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
ES2268705T3
(es)
|
1995-06-01 |
2007-03-16 |
Kishimoto, Tadamitsu |
Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
GB9515975D0
(en)
|
1995-08-04 |
1995-10-04 |
Zeneca Ltd |
Chemical compounds
|
US6167301A
(en)
|
1995-08-29 |
2000-12-26 |
Flower; Ronald J. |
Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
|
WO1997007788A2
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
US5863904A
(en)
|
1995-09-26 |
1999-01-26 |
The University Of Michigan |
Methods for treating cancers and restenosis with P21
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
US6576754B2
(en)
|
1995-11-09 |
2003-06-10 |
Dana-Farber Cancer Institute |
CD100 antigen and uses therefor
|
US6127366A
(en)
|
1995-11-22 |
2000-10-03 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2231105C
(en)
|
1995-12-08 |
2005-09-13 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
US5958769A
(en)
|
1996-01-18 |
1999-09-28 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for mediating cell cycle progression
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
US6090948A
(en)
|
1996-01-30 |
2000-07-18 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
EP0944387A1
(en)
|
1996-01-30 |
1999-09-29 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
DK0885002T3
(da)
|
1996-03-04 |
2011-08-22 |
Penn State Res Found |
Materialer og fremgangsmåder til forøgelse af cellulær internalisering
|
AU5711196A
(en)
|
1996-03-14 |
1997-10-01 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
DE69731289D1
(de)
|
1996-03-18 |
2004-11-25 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
CA2248868A1
(en)
|
1996-03-22 |
1997-09-25 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule ii
|
US6080870A
(en)
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6063930A
(en)
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5891889A
(en)
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
US5648239A
(en)
|
1996-06-21 |
1997-07-15 |
Incyte Pharmaceuticals, Inc. |
Human camp-dependent protein kinase inhibitor homolog
|
BR9709974A
(pt)
|
1996-06-27 |
1999-08-10 |
Pfizer |
Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
|
DE69738166T2
(de)
|
1996-06-27 |
2008-06-19 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
NL1003648C2
(nl)
|
1996-07-19 |
1998-01-21 |
Carino Cornelis Sunderman |
Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
|
NZ334613A
(en)
|
1996-08-12 |
2002-02-01 |
Welfide Corp |
Pharmaceutical agents comprising Rho kinase inhibitor
|
US5985317A
(en)
|
1996-09-06 |
1999-11-16 |
Theratech, Inc. |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
|
US5945429A
(en)
|
1996-09-13 |
1999-08-31 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6040305A
(en)
|
1996-09-13 |
2000-03-21 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6030982A
(en)
|
1996-09-13 |
2000-02-29 |
Schering Corporationm |
Compounds useful for inhibition of farnesyl protein transferase
|
DE69736860T2
(de)
|
1996-09-24 |
2007-05-16 |
Merck & Co., Inc. |
Verbindungen zur hemmung der angiogenese durch gentherapie
|
US5885834A
(en)
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
BR9711585A
(pt)
|
1996-10-01 |
2000-01-18 |
Cima Labs Inc |
Composição de microcápsula, com sabor mascarado, de um remédio solúvel em água, formulação farmacêutica para administrar um remédio, e, processo para disfarçar o sabor de um remédio.
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
ES2301183T3
(es)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
Anticuerpo completamente humano que se une al receptor del egfr.
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
US6093737A
(en)
|
1996-12-30 |
2000-07-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6013662A
(en)
|
1996-12-30 |
2000-01-11 |
Rhone-Poulenc Rorer S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US5939439A
(en)
|
1996-12-30 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2277801C
(en)
|
1997-01-16 |
2002-10-15 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
EP0975603A1
(en)
|
1997-01-29 |
2000-02-02 |
Zeneca Limited |
Inhibitors of farnesyl protein transferase
|
US5860957A
(en)
|
1997-02-07 |
1999-01-19 |
Sarcos, Inc. |
Multipathway electronically-controlled drug delivery system
|
ZA981080B
(en)
|
1997-02-11 |
1998-08-12 |
Warner Lambert Co |
Bicyclic inhibitors of protein farnesyl transferase
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
US20070055056A1
(en)
|
1997-03-07 |
2007-03-08 |
Rosen Craig A |
251 human secreted proteins
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
US20080103090A1
(en)
|
1997-03-07 |
2008-05-01 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
US20060223090A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Polynucleotides encoding human secreted proteins
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
US20060246483A1
(en)
|
1997-03-07 |
2006-11-02 |
Rosen Craig A |
337 human secreted proteins
|
US20070015696A1
(en)
|
1997-03-07 |
2007-01-18 |
Rosen Craig A |
621 human secreted proteins
|
US7968689B2
(en)
|
1997-03-07 |
2011-06-28 |
Human Genome Sciences, Inc. |
Antibodies to HSDEK49 polypeptides
|
TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
RU2224766C2
(ru)
|
1997-04-14 |
2004-02-27 |
Микромет Аг |
Способ получения рецепторов для человеческих антигенов и их применение
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6239140B1
(en)
|
1997-06-17 |
2001-05-29 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6051582A
(en)
|
1997-06-17 |
2000-04-18 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6159984A
(en)
|
1997-06-17 |
2000-12-12 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6211193B1
(en)
|
1997-06-17 |
2001-04-03 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6225322B1
(en)
|
1997-06-17 |
2001-05-01 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6228865B1
(en)
|
1997-06-17 |
2001-05-08 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
EA002550B1
(ru)
|
1997-06-20 |
2002-06-27 |
Байоджен, Инк. |
Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
|
US6075007A
(en)
|
1997-07-17 |
2000-06-13 |
Regeneron Pharmaceuticals, Inc. |
Modified noggin polypeptide and compositions
|
AR013184A1
(es)
|
1997-07-18 |
2000-12-13 |
Astrazeneca Ab |
Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
|
HUP0003194A3
(en)
|
1997-08-15 |
2003-03-28 |
Cephalon Inc West Chester |
Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
|
US5948433A
(en)
|
1997-08-21 |
1999-09-07 |
Bertek, Inc. |
Transdermal patch
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
AU752433B2
(en)
|
1997-09-23 |
2002-09-19 |
Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts |
Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
US6103723A
(en)
|
1997-10-17 |
2000-08-15 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
DK1025088T3
(da)
|
1997-10-22 |
2001-11-12 |
Astrazeneca Ab |
Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorer
|
JP2001520222A
(ja)
|
1997-10-22 |
2001-10-30 |
ゼネカ・リミテッド |
イミダゾール誘導体およびファルネシルタンパク質トランスフェラーゼインヒビターとしてのそれらの使用
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
CA2275539A1
(en)
|
1997-10-28 |
1999-05-06 |
Bando Chemical Industries, Ltd. |
A transdermal patch and a method for manufacture of a substrate sheet therefor
|
CA2309541C
(en)
|
1997-11-03 |
2011-01-11 |
Human Genome Sciences, Inc. |
Vegi, an inhibitor of angiogenesis and tumor growth
|
US6124465A
(en)
|
1997-11-25 |
2000-09-26 |
Rhone-Poulenc S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
AU731272B2
(en)
|
1997-11-28 |
2001-03-29 |
Lg Chemical Ltd. |
Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
|
US6054466A
(en)
|
1997-12-04 |
2000-04-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
DE69824039T2
(de)
|
1997-12-08 |
2005-08-18 |
Lexigen Pharmaceuticals Corp., Lexington |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
US6242196B1
(en)
|
1997-12-11 |
2001-06-05 |
Dana-Farber Cancer Institute |
Methods and pharmaceutical compositions for inhibiting tumor cell growth
|
US6335156B1
(en)
|
1997-12-18 |
2002-01-01 |
The Johns Hopkins University School Of Medicine |
14-3-3σ arrests the cell cycle
|
ATE229017T1
(de)
|
1998-02-02 |
2002-12-15 |
Lg Chemical Ltd |
Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
|
JP2002505086A
(ja)
|
1998-02-25 |
2002-02-19 |
レキシジェン ファーマシューティカルズ コーポレイション |
抗体ベースの融合タンパク質の循環半減期の増強
|
WO1999048927A1
(en)
|
1998-03-25 |
1999-09-30 |
Cornell Research Foundation, Inc. |
Methods for designing specific ion channel blockers
|
CN1318092C
(zh)
|
1998-04-15 |
2007-05-30 |
利思进药品公司 |
含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
|
EP1071469A2
(en)
|
1998-04-17 |
2001-01-31 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
|
PT1076663E
(pt)
|
1998-04-27 |
2004-06-30 |
Warner Lambert Co |
Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
CA2336139C
(en)
|
1998-06-24 |
2008-10-14 |
Advanced Inhalation Research, Inc. |
Large porous particles emitted from an inhaler
|
EE04579B1
(et)
|
1998-07-06 |
2006-02-15 |
Janssen Pharmaceutica N.V. |
Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
|
US6034053A
(en)
|
1998-07-13 |
2000-03-07 |
Wayne Hughes Institute |
EGF-isoflavone conjugates for the prevention of restenosis
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
HUP0103329A3
(en)
|
1998-08-25 |
2003-09-29 |
Lexigen Pharmaceuticals Corp L |
Expression and export of angiostatin and endostatin as immunofusis
|
US6362188B1
(en)
|
1998-12-18 |
2002-03-26 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6372747B1
(en)
|
1998-12-18 |
2002-04-16 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
FR2787327B1
(fr)
|
1998-12-21 |
2003-01-17 |
Aventis Pharma Sa |
Compositions contenant des inhibiteurs de farnesyle transferase
|
US6432959B1
(en)
|
1998-12-23 |
2002-08-13 |
Schering Corporation |
Inhibitors of farnesyl-protein transferase
|
KR20020007287A
(ko)
|
1999-01-07 |
2002-01-26 |
추후보정 |
Fc 융합 단백질로서 항-비만 단백질의 발현 및 이출
|
JP4876239B2
(ja)
|
1999-01-11 |
2012-02-15 |
プリンストン ユニバーシティー |
標的確認のための高親和性阻害剤およびその使用
|
TR200102021T2
(tr)
|
1999-01-15 |
2001-12-21 |
Biogen, Inc. |
TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
AU776790B2
(en)
|
1999-02-12 |
2004-09-23 |
Lexigen Pharmaceuticals Corporation |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
|
US6245759B1
(en)
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
GB9907965D0
(en)
|
1999-04-09 |
1999-06-02 |
Glaxo Group Ltd |
Medical use
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US6143766A
(en)
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
ES2223705T3
(es)
|
1999-04-28 |
2005-03-01 |
Board Of Regents, The University Of Texas System |
Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
US6256533B1
(en)
|
1999-06-09 |
2001-07-03 |
The Procter & Gamble Company |
Apparatus and method for using an intracutaneous microneedle array
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
DK1200479T3
(da)
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
US20030119038A1
(en)
|
1999-09-09 |
2003-06-26 |
Bingham Brendan William |
NARC1, novel subtilase-like homologs
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
US20100291099A1
(en)
|
1999-09-27 |
2010-11-18 |
Millennium Pharmaceuticals, Inc. |
Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
|
US20020081679A1
(en)
|
1999-10-22 |
2002-06-27 |
Millennium Pharmaceuticals, Inc. |
NARC8 programmed cell-death-associated molecules and uses thereof
|
US20110230392A1
(en)
|
1999-10-22 |
2011-09-22 |
Millennium Pharmaceuticals, Inc. |
Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
|
AU1099601A
(en)
|
1999-10-22 |
2001-05-08 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules derived from rat brain and programmed cell death models
|
WO2001044301A1
(en)
|
1999-11-29 |
2001-06-21 |
Unilever Plc |
Immobilized single domain antigen-binding molecules
|
TWI263496B
(en)
|
1999-12-10 |
2006-10-11 |
Novartis Ag |
Pharmaceutical combinations and their use in treating gastrointestinal disorders
|
US6403581B1
(en)
|
2000-01-19 |
2002-06-11 |
American Cyanamid Company |
Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
|
EP1257572A2
(en)
|
2000-02-07 |
2002-11-20 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
CN1406249B
(zh)
|
2000-02-11 |
2010-06-16 |
默克专利股份有限公司 |
增加基于抗体的融合蛋白的循环半衰期
|
US6261595B1
(en)
|
2000-02-29 |
2001-07-17 |
Zars, Inc. |
Transdermal drug patch with attached pocket for controlled heating device
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
US6680315B2
(en)
|
2000-06-15 |
2004-01-20 |
Synta Pharmaceuticals Corp. |
Triazine compounds
|
CA2411971A1
(en)
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
Proteases
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
ATE368475T1
(de)
|
2000-06-29 |
2007-08-15 |
Emd Lexigen Res Ct Corp |
Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
EP1309614A2
(en)
|
2000-08-11 |
2003-05-14 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
CN1203857C
(zh)
|
2000-09-18 |
2005-06-01 |
威克斯医药有限公司 |
局部麻醉与镇痛的新方法
|
CN1284536C
(zh)
|
2000-09-18 |
2006-11-15 |
威克斯医药有限公司 |
河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
|
AU2001296908A1
(en)
|
2000-09-29 |
2002-04-08 |
Geneva Pharmaceuticals, Inc. |
Proton pump inhibitor formulation
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
AU2002227280A1
(en)
|
2000-12-08 |
2002-06-18 |
Incyte Genomics, Inc. |
Protein modification and maintenance molecules
|
WO2002057435A2
(en)
|
2001-01-18 |
2002-07-25 |
Merck Patent Gmbh |
Bifunctional fusion proteins with glucocerebrosidase activity
|
AU2002233340B2
(en)
|
2001-02-19 |
2008-05-22 |
Merck Patent Gmbh |
Artificial fusion proteins with reduced immunogenicity
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
PL206701B1
(pl)
|
2001-03-07 |
2010-09-30 |
Merck Patent Gmbh |
Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
|
EP1379264A4
(en)
|
2001-03-21 |
2009-07-08 |
Human Genome Sciences Inc |
HUMAN SECRETED PROTEINS
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
WO2002086083A2
(en)
|
2001-04-20 |
2002-10-31 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
PL205352B1
(pl)
|
2001-05-03 |
2010-04-30 |
Merck Patent Gmbh |
Rekombinowane przeciwciało specyficzne dla nowotworu
|
DE60225914T2
(de)
|
2001-05-23 |
2009-07-23 |
Bristol-Myers Squibb Co. |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
|
US20040023243A1
(en)
|
2001-06-13 |
2004-02-05 |
Yue Henry |
Proteases
|
JP2005500034A
(ja)
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
US20030124149A1
(en)
|
2001-07-06 |
2003-07-03 |
Shalaby Shalaby W. |
Bioactive absorbable microparticles as therapeutic vaccines
|
US20040038242A1
(en)
|
2001-07-30 |
2004-02-26 |
Edmonds Brian Taylor |
Novel secreted proteins and their uses
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
CA2466698A1
(en)
|
2001-11-09 |
2003-05-15 |
Medigene Aktiengesellschaft |
Cellular vaccines comprising adjuvants
|
JP4795640B2
(ja)
|
2001-12-04 |
2011-10-19 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
調節された選択性を有する免疫サイトカイン
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
US20050214857A1
(en)
|
2001-12-11 |
2005-09-29 |
Algonomics N.V. |
Method for displaying loops from immunoglobulin domains in different contexts
|
WO2003059245A2
(en)
*
|
2001-12-18 |
2003-07-24 |
J & J Research Pty Ltd |
Method of treating asthma
|
US20060093771A1
(en)
|
2002-02-15 |
2006-05-04 |
Frantisek Rypacek |
Polymer coating for medical devices
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
WO2003074679A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
PT2206517T
(pt)
|
2002-07-03 |
2023-11-07 |
Tasuku Honjo |
Composições de imunopotenciação contendo anticorpos anti-pd-l1
|
US6875433B2
(en)
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
PT1570267E
(pt)
|
2002-12-03 |
2012-01-03 |
Ucb Pharma Sa |
Ensaio para a identificação de células produtoras de anticorpos
|
AU2003298187B2
(en)
|
2002-12-17 |
2010-09-16 |
Merck Patent Gmbh |
Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
|
MXPA05007019A
(es)
|
2002-12-30 |
2005-08-18 |
Amgen Inc |
Terapia de combinacion con factores co-estimuladores.
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
AU2004270103B2
(en)
|
2003-05-21 |
2012-02-23 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies against Bacillusanthracis protective antigen
|
WO2005007809A2
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
US7354578B2
(en)
|
2003-06-06 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with VEGF inhibitors
|
WO2005003169A2
(en)
|
2003-07-01 |
2005-01-13 |
Celltech R & D Limited |
Modified antibody fab fragments
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
CA2537055A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
JP2005130764A
(ja)
|
2003-10-30 |
2005-05-26 |
Pharmaceuticals & Medical Devices Agency |
Narc−1遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
|
PL1699822T3
(pl)
|
2003-12-30 |
2008-08-29 |
Merck Patent Gmbh |
Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
|
CN1902222A
(zh)
|
2003-12-31 |
2007-01-24 |
默克专利有限公司 |
具有改善药物代谢动力学的Fc-促红细胞生成素融合蛋白质
|
CA2552590A1
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005091956A2
(en)
|
2004-03-05 |
2005-10-06 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
US20060002929A1
(en)
|
2004-03-23 |
2006-01-05 |
Khare Sanjay D |
Monoclonal antibodies
|
US7998481B2
(en)
|
2004-04-05 |
2011-08-16 |
The Regents Of The University Of California |
Modulation of NKG2D for treating or preventing solid organ allograft rejection
|
JP5848861B2
(ja)
|
2004-04-20 |
2016-01-27 |
ジェンマブ エー/エスGenmab A/S |
Cd20に対するヒトモノクローナル抗体
|
AU2005235718B2
(en)
|
2004-04-23 |
2011-09-22 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten |
Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
|
GB0411186D0
(en)
|
2004-05-19 |
2004-06-23 |
Celltech R&D Ltd |
Biological products
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
GB0412986D0
(en)
|
2004-06-10 |
2004-07-14 |
Xention Discovery Ltd |
Compounds
|
JP2008503481A
(ja)
|
2004-06-18 |
2008-02-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
悪性胸膜滲出液の処置のためのvegfインヒビターの投与および使用の方法
|
EP1768695A4
(en)
|
2004-06-29 |
2008-07-30 |
Univ Johns Hopkins |
IMPROVEMENT OF MEDICINE-INDUCED TOXICITY
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
CN101023102B
(zh)
|
2004-09-17 |
2013-05-29 |
霍夫曼-拉罗奇有限公司 |
抗-ox40l抗体
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
AU2005313492B2
(en)
|
2004-12-09 |
2011-12-15 |
Merck Patent Gmbh |
IL-7 variants with reduced immunogenicity
|
US7973140B2
(en)
|
2004-12-21 |
2011-07-05 |
Medimmune Limited |
Antibodies directed to angiopoietin-2 and uses thereof
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
TW200641353A
(en)
|
2005-02-14 |
2006-12-01 |
Wyeth Corp |
Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
|
US7981605B2
(en)
|
2005-02-24 |
2011-07-19 |
Amgen Inc. |
Epidermal growth factor receptor mutations
|
EP1855708A1
(en)
|
2005-03-11 |
2007-11-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of vegf
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
NZ601439A
(en)
|
2005-06-08 |
2012-11-30 |
Brigham & Womens Hospital |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
CA3201163A1
(en)
|
2005-07-01 |
2007-01-11 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
MX2008001966A
(es)
|
2005-08-12 |
2008-03-26 |
Regeneron Pharma |
Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
|
GB0517487D0
(en)
|
2005-08-26 |
2005-10-05 |
Isis Innovation |
Antibodies
|
US7972813B2
(en)
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
TWI461436B
(zh)
*
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
AR057253A1
(es)
|
2005-12-16 |
2007-11-21 |
Genentech Inc |
Anticuerpos anti-ox40l y metodos que los utilizan
|
US10508144B2
(en)
|
2005-12-20 |
2019-12-17 |
Bristol-Myers Squibb Company |
Carbohydrate content of CTLA4 molecules
|
WO2007109324A2
(en)
|
2006-03-21 |
2007-09-27 |
Xenon Pharmaceuticals, Inc. |
Potent and selective nav 1.7 sodium channel blockers
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
EP2348106B1
(en)
|
2006-05-08 |
2014-07-02 |
Adaerata, Limited Partnership |
Chimeric proteins, cells comprising same, and assays using same
|
US7605251B2
(en)
|
2006-05-11 |
2009-10-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
TW201343676A
(zh)
|
2006-08-28 |
2013-11-01 |
Kyowa Hakko Kirin Co Ltd |
具拮抗性之人類light專一性人類單株抗體
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
US20100068194A1
(en)
|
2006-10-24 |
2010-03-18 |
Dong-Ku Kim |
Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
|
CA2668131A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
CA2669424A1
(en)
|
2006-11-07 |
2008-05-29 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
WO2008057458A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
WO2008133647A2
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
SI2079760T1
(sl)
|
2006-12-27 |
2016-11-30 |
Emory University |
Sestavki in metode za zdravljenje okužb
|
AU2008204901A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-IL-13 antibody formulations and uses thereof
|
WO2008090958A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ドメイン交換された遺伝子組換え抗体組成物
|
AU2008219666A1
(en)
|
2007-02-27 |
2008-09-04 |
Genentech, Inc. |
Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
WO2008109871A2
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
EA200901376A1
(ru)
|
2007-04-13 |
2010-12-30 |
Новартис Аг |
Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
|
WO2008130704A2
(en)
|
2007-04-17 |
2008-10-30 |
Imclone Llc |
PDGFRβ-SPECIFIC INHIBITORS
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
BRPI0818094A2
(pt)
|
2007-10-09 |
2015-07-14 |
Rentech Inc |
Método para remover alcatrão de um gás, e, sistema e método de gaseificação de biomassa
|
EP2205639B1
(en)
|
2007-10-26 |
2015-12-23 |
Merck Sharp & Dohme Corp. |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
US9176122B2
(en)
|
2008-03-24 |
2015-11-03 |
University Of South Florida |
Biomarkers for predicting response to immunosuppressive therapy
|
KR101924831B1
(ko)
|
2008-04-09 |
2018-12-05 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
MX2010011499A
(es)
|
2008-04-23 |
2010-11-12 |
Amgen Inc |
Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
CA2736198A1
(en)
*
|
2008-09-19 |
2010-03-25 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
AU2009313560B2
(en)
*
|
2008-11-07 |
2016-04-14 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
CN102265534B
(zh)
|
2008-12-23 |
2014-08-20 |
皇家飞利浦电子股份有限公司 |
组合身体耦合通信和射频通信
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille |
Pd−1抗体およびpd−l1抗体ならびにその使用
|
MY157473A
(en)
|
2009-02-17 |
2016-06-15 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human ox40
|
AU2010228990A1
(en)
|
2009-03-24 |
2011-10-27 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against LIGHT and uses thereof
|
WO2010117448A2
(en)
|
2009-04-05 |
2010-10-14 |
Provenance Biopharmaceuticals Corp. |
Chimeric immunocytokines and methods of use thereof
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
EP2564695B1
(en)
|
2009-07-08 |
2015-04-15 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
MX2012002014A
(es)
|
2009-08-17 |
2012-06-13 |
Roche Glycart Ag |
Inmunoconjugados dirigidos.
|
WO2011025904A1
(en)
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
WO2011032112A2
(en)
|
2009-09-11 |
2011-03-17 |
University Of Utah Research Foundation |
Mutant sodium channel nav1.7 and methods related thereto
|
US20120219558A1
(en)
|
2009-09-25 |
2012-08-30 |
Yan Ni |
Antagonists of pcsk9
|
WO2011041613A2
(en)
|
2009-09-30 |
2011-04-07 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
CA2777698A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
WO2011053665A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
CA2777695A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
EP2493507A4
(en)
|
2009-10-30 |
2013-11-20 |
Merck Sharp & Dohme |
ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
|
CA2780221A1
(en)
*
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
US9005619B2
(en)
|
2009-12-07 |
2015-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
US9133436B2
(en)
|
2010-02-04 |
2015-09-15 |
The Trustees Of The University Of Pennsylvania |
ICOS critically regulates the expansion and function of inflammatory human Th17 cells
|
BR112012022917A2
(pt)
|
2010-03-11 |
2017-01-10 |
Pfizer |
anticorpos com ligação a antígeno dependente de ph
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
EA022983B1
(ru)
|
2010-04-13 |
2016-04-29 |
Бристол-Майерс Сквибб Компани |
Белки на основе структурного домена фибронектина, связывающие pcsk9
|
EP3466977B1
(en)
|
2010-04-16 |
2022-01-05 |
Biogen MA Inc. |
Anti-vla-4 antibodies
|
US8871996B2
(en)
|
2010-06-09 |
2014-10-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing human voltage-gated sodium channels
|
US8486647B2
(en)
|
2010-06-09 |
2013-07-16 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
CN103228130B
(zh)
|
2010-06-17 |
2016-03-16 |
科马布有限公司 |
动物模型及治疗分子
|
MX339964B
(es)
|
2010-08-23 |
2016-06-17 |
Board Of Regents The Univ Of Texas System * |
Anticuerpos anti-ox40 y metodos para usarlos.
|
MX340555B
(es)
*
|
2010-08-25 |
2016-07-14 |
F Hoffmann-La Roche Ag * |
Anticuerpos contra il-18r1 y usos de los mismos.
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
AR084456A1
(es)
|
2010-12-22 |
2013-05-15 |
Genentech Inc |
Anticuerpo anti-pcsk9 y metodos de uso
|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
|
CN103492575A
(zh)
|
2011-01-18 |
2014-01-01 |
安姆根有限公司 |
NaV1.7敲除小鼠及其用途
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
EP2668212B1
(en)
|
2011-01-28 |
2018-03-21 |
Sanofi Biotechnology |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
JP2014511378A
(ja)
|
2011-02-11 |
2014-05-15 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Pcsk9アンタゴニスト
|
WO2012132067A1
(ja)
*
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
PT2683406T
(pt)
|
2011-03-11 |
2019-07-08 |
Beth Israel Deaconess Medical Ct Inc |
Anticorpos anti-cd40 e utilização dos mesmos
|
US9376493B2
(en)
|
2011-03-31 |
2016-06-28 |
INSERM (Institut National de la Sante et de la Recherche Mediacale) |
Antibodies directed against ICOS and uses thereof
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US9732196B2
(en)
|
2011-05-10 |
2017-08-15 |
Sabic Global Technologies B.V. |
Adhesive for bonding polyimide resins
|
WO2012162583A1
(en)
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
US9574002B2
(en)
*
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
CA2841416A1
(en)
|
2011-06-15 |
2012-12-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of selecting therapeutic indications
|
MX2013015311A
(es)
|
2011-06-20 |
2014-03-31 |
Genentech Inc |
Polipeptidos de enlace de pcsk9 y metodos de uso.
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
LT2731677T
(lt)
|
2011-07-11 |
2018-07-10 |
Glenmark Pharmaceuticals S.A. |
Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
|
KR20140021708A
(ko)
|
2011-07-14 |
2014-02-20 |
화이자 인코포레이티드 |
항-pcsk9 항체를 사용한 치료
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
KR101685262B1
(ko)
*
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ox40 항체 및 이의 사용 방법
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
CN111789944A
(zh)
|
2011-09-16 |
2020-10-20 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
CN106995822B
(zh)
|
2011-09-19 |
2021-06-29 |
科马布有限公司 |
定制供人类使用的抗体、可变结构域和链
|
TWI585102B
(zh)
|
2011-10-13 |
2017-06-01 |
必治妥美雅史谷比公司 |
拮抗cd40l之抗體多肽
|
EA201992617A1
(ru)
*
|
2011-10-26 |
2020-03-10 |
Амген Инк. |
Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
US20130115171A1
(en)
|
2011-11-09 |
2013-05-09 |
Stefan I. McDonough |
Nav1.7-related assays
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2013119202A1
(en)
|
2012-02-06 |
2013-08-15 |
Providence Health & Services - Oregon |
Cancer treatment and monitoring methods using ox40 agonists
|
WO2013148350A2
(en)
|
2012-03-26 |
2013-10-03 |
Sanofi |
Anti-light antibody therapy for inflammatory bowel disease
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
WO2013172933A1
(en)
|
2012-05-15 |
2013-11-21 |
University Of Southern California |
Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
|
SG10201700698WA
(en)
|
2012-05-15 |
2017-02-27 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
EP2849788B1
(en)
|
2012-05-17 |
2018-01-03 |
Cyon Therapeutics Inc. |
Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
|
US9102751B2
(en)
|
2012-05-18 |
2015-08-11 |
Janssen Biotech, Inc. |
Huwentoxin-IV variants and methods of use
|
WO2013180201A1
(ja)
*
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
ES2848732T3
(es)
|
2012-08-07 |
2021-08-11 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
MX2015003416A
(es)
|
2012-09-17 |
2015-10-29 |
Galectin Therapeutics Inc |
Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
|
JP6461800B2
(ja)
|
2012-10-04 |
2019-01-30 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ヒトモノクローナル抗pd−l1抗体および使用方法
|
RS58528B1
(sr)
|
2012-12-03 |
2019-04-30 |
Bristol Myers Squibb Co |
Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
CA2897826C
(en)
|
2013-01-09 |
2022-09-27 |
Taylor H. Schreiber |
Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
CN110478481A
(zh)
|
2013-03-13 |
2019-11-22 |
比奥阿赛斯技术有限公司 |
p97片段及其应用
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
WO2014159562A1
(en)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
AU2014240392A1
(en)
|
2013-03-14 |
2015-11-05 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to Nav1.7
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
MX370818B
(es)
|
2013-09-11 |
2020-01-08 |
Medimmune Ltd |
Anticuerpos anti-b7-h1 para tratar tumores.
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
CA2926856A1
(en)
|
2013-10-25 |
2015-04-30 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
US10751370B2
(en)
|
2013-12-13 |
2020-08-25 |
Swedish Stromabio Ab |
Immunomodulatory compositions
|
HRP20220214T1
(hr)
|
2014-01-15 |
2022-04-29 |
Kadmon Corporation, Llc |
Imunomodulacijska sredstva
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
PL3102595T3
(pl)
|
2014-02-06 |
2019-04-30 |
Hoffmann La Roche |
Białka fuzyjne interleukiny-2 i ich zastosowania
|
GB201403775D0
(en)
*
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
RU2690670C2
(ru)
|
2014-03-12 |
2019-06-05 |
Ида Рисерч Энд Дивелопмент Ко., Лтд |
Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
WO2015173267A1
(en)
|
2014-05-13 |
2015-11-19 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
US9885721B2
(en)
|
2014-05-29 |
2018-02-06 |
Spring Bioscience Corporation |
PD-L1 antibodies and uses thereof
|
WO2016000619A1
(en)
|
2014-07-03 |
2016-01-07 |
Beigene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
CN106604933B
(zh)
|
2014-07-11 |
2021-08-10 |
文塔纳医疗系统公司 |
抗pd-l1抗体及其诊断用途
|
EP3194445A4
(en)
|
2014-08-04 |
2018-05-23 |
Baylor Research Institute |
Antagonistic anti-ox40l antibodies and methods of their use
|
NZ766660A
(en)
|
2014-08-05 |
2024-02-23 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
IL250583B
(en)
|
2014-08-19 |
2022-07-01 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
HUE047806T2
(hu)
|
2014-08-29 |
2020-05-28 |
Hoffmann La Roche |
Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
|
MA40035A
(fr)
|
2014-10-14 |
2016-04-21 |
Dana Farber Cancer Inst Inc |
Molécules d'anticorps de pd-l1 et leurs utilisations
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
CN114504651A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
US20220372153A1
(en)
|
2015-03-03 |
2022-11-24 |
Kymab Limited |
Synergistic combinations of ox40l antibodies for the treatment of gvhd
|
US9512229B2
(en)
*
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
US10023635B2
(en)
|
2015-03-23 |
2018-07-17 |
Jounce Therapeutics, Inc. |
Antibodies to ICOS
|
WO2016160792A1
(en)
|
2015-03-30 |
2016-10-06 |
Stcube & Co., Inc. |
Antibodies specific to glycosylated pd-l1 and methods of use thereof
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
JP6976241B2
(ja)
|
2015-08-14 |
2021-12-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗tigit抗体
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
EP3344658B1
(en)
|
2015-09-02 |
2022-05-11 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
WO2017053748A2
(en)
|
2015-09-25 |
2017-03-30 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
ES2910027T3
(es)
|
2015-10-01 |
2022-05-11 |
Potenza Therapeutics Inc |
Proteínas de unión a antígeno anti-TIGIT y métodos de uso de las mismas
|
CN108350505A
(zh)
|
2015-10-22 |
2018-07-31 |
震动疗法股份有限公司 |
用于测定icos表达的基因标志
|
US20180346571A1
(en)
|
2015-11-17 |
2018-12-06 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
AU2016355568A1
(en)
|
2015-11-18 |
2018-06-21 |
Merck Sharp & Dohme Llc |
PD1/CTLA4 Binders
|
WO2017091429A1
(en)
|
2015-11-24 |
2017-06-01 |
Eli Lilly And Company |
Combination therapy for cancer
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
US10118963B2
(en)
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
CN107151269B
(zh)
|
2016-03-04 |
2021-07-27 |
四川科伦博泰生物医药股份有限公司 |
一种pdl-1抗体、其药物组合物及其用途
|
CN109311985B
(zh)
|
2016-05-09 |
2022-09-30 |
Igm生物科学股份有限公司 |
抗pd-l1抗体
|
CN105968200B
(zh)
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
EP3463482B1
(en)
|
2016-06-07 |
2021-10-06 |
The Brigham and Women's Hospital, Inc. |
Methods relating to t peripheral helper cells in autoantibody-associated conditions
|
CN109414500B
(zh)
|
2016-06-13 |
2022-02-25 |
奥美药业有限公司 |
治疗和诊断用pd-l1特异性单克隆抗体
|
WO2017215590A1
(en)
|
2016-06-13 |
2017-12-21 |
I-Mab |
Anti-pd-l1 antibodies and uses thereof
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
DK3472207T3
(da)
|
2016-06-20 |
2021-04-12 |
F Star Delta Ltd |
Bindingsmolekyler, der binder pd-l1 og lag-3
|
WO2018005682A2
(en)
|
2016-06-29 |
2018-01-04 |
Checkpoint Therapeutics, Inc. |
Pd-l1-specific antibodies and methods of using the same
|
JP7093771B2
(ja)
|
2016-07-07 |
2022-06-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
プログラム死1リガンド1(pd-l1)結合タンパク質及びその使用方法
|
US11274153B2
(en)
|
2016-08-04 |
2022-03-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-PD-L1 nanobody and use thereof
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
BR112019002282A2
(pt)
|
2016-08-05 |
2019-07-16 |
Y Biologics Inc |
anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
IL300982B1
(en)
|
2016-09-10 |
2024-04-01 |
Yeda Res & Dev |
Reduction of the level of regulatory T cells or their activity for the treatment of diseases and damages in the central nervous system
|
CA3037230A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
KR102543323B1
(ko)
|
2016-10-30 |
2023-06-14 |
상하이 헨리우스 바이오테크, 인크. |
항-pd-l1 항체 및 변이체
|
PT3535298T
(pt)
|
2016-11-02 |
2021-11-25 |
Jounce Therapeutics Inc |
Anticorpos para pd-1 e seu uso
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
EP3559045A4
(en)
|
2016-12-23 |
2020-08-19 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
|
EP3571228A1
(en)
|
2017-01-18 |
2019-11-27 |
H. Hoffnabb-La Roche Ag |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
BR112019018533A2
(pt)
|
2017-03-09 |
2020-04-14 |
Genmab As |
anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para tratar uma doença, e, uso de um anticorpo
|
WO2018187191A1
(en)
|
2017-04-03 |
2018-10-11 |
Jounce Therapeutics, Inc |
Compositions and methods for the treatment of cancer
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MA50038A
(fr)
|
2017-04-18 |
2020-07-08 |
R Pharm Overseas Inc |
Anticorps anti-pd-l1 de et son utilisation
|
KR20200016899A
(ko)
|
2017-06-01 |
2020-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항-pdl1 항체, 및 이의 이용 방법
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
US10442866B1
(en)
|
2019-01-23 |
2019-10-15 |
Beijing Mabworks Biotech Co. Ltd |
Antibodies binding OX40 and uses thereof
|